HC Wainwright Rates Biodesix (BDSX) buy, $26 Price Target

HC Wainwright maintains its Buy rating on BDSX, setting a $26 price target, a 72.64% upside from the current price.

By EarningsIQ Research Desk · Published Jun 15, 2026, 7:01 AM EDT · Updated Jun 16, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Biodesix, Inc. ($BDSX) "buy" with a $26 price target on June 15, 2026.

Since the rating, $BDSX is up 11.2% after 1 week, up 34.6% after 1 month and up 51.7% to date (from the $15.60 close on Jun 15, 2026).

BDSX Biodesix, Inc.

$23.66 +266.25% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its Buy rating on BDSX on June 15, 2026, with a price target of $26.
HC Wainwright's $26 price target implies 72.64% upside from Biodesix, Inc.'s ($BDSX) current $15.06 share price.
BDSX shares are currently trading at $15.06, with insider trading activity noted in March 2026.
Peer funds like AIGH Capital and Telemark Asset Management have adjusted their holdings in BDSX.

Get $BDSX trade alerts by text

We text you when insiders, Congress or big funds trade $BDSX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Biodesix, Inc. alert may contain errors. Disclosures

HC Wainwright reiterated its Buy rating on BDSX on June 15, 2026, setting a price target of $26. This reaffirmation suggests continued confidence in the company's prospects. Shares of BDSX are currently trading at $15.06.

Other Institutional Activity in BDSX

Several institutional investors have recently adjusted their positions in BDSX. AIGH Capital Management LLC initiated a position with 758,328 shares, valued at approximately $10.99 million. Telemark Asset Management, LLC increased its holdings by 162,000 shares to a total of 489,824 shares, worth about $7.10 million. Aberdeen Group PLC also grew its stake by 196,013 shares, reaching 458,438 shares valued at roughly $6.65 million.

Biodesix, Inc. Stock Down 48.4%

BDSX shares are trading at $15.06. The stock has attracted attention from investors, partly due to its recent analyst ratings and institutional activity. The market is watching closely to see if BDSX can reach the price targets set by analysts.

12-month forecast

$BDSX price target

Biodesix, Inc. daily closes and this analyst's $26 target. Not advice.

Insider Buying and Selling at Biodesix, Inc.

Insider trading activity at BDSX included several sales on February 23, 2026. Robin Harper Cowie, the CFO, Secretary, and Treasurer, sold 535 shares at an average price of $12.78. Chris Vazquez, the Chief Accounting Officer, sold 211 shares at the same price. Additionally, Chief Commercial Officer Kieran O'Kane and President & CEO Scott Hutton sold 535 and 1,490 shares, respectively.

Analysts Set New Price Targets

On June 15, 2026, HC Wainwright reiterated its Buy rating on BDSX with a $26 price target. Previously, on May 5, 2026, Canaccord Genuity maintained its Buy rating with a $22 target. The consensus among analysts remains positive, with a general Buy recommendation and a mean target price reflecting optimism about BDSX's future performance.

Bottom Line

HC Wainwright's reaffirmation of its Buy rating for BDSX, with a $26 target, highlights ongoing analyst confidence. Investors are likely to keep an eye on BDSX, especially given the recent institutional and insider activities. As always, 13F filings and insider trades are backward-looking and may not reflect current positions.